Today, we will see why Arena Pharmaceuticals (ARNA) is an attractive pick in March 2020.
Company overview
Arena Pharmaceuticals is a biopharmaceutical company with four clinical-stage assets, Etrasimod, Olorinab, APD418, and Ralinepag partnership, which are being evaluated across eight disease conditions. The company also has four major preclinical assets.
The years 2020 and 2021 are expected to be catalyst-rich ones for the company with two Phase 3 readouts, six Phase 2 readouts, and two INDs. The company now expects one IND per year for the next five years.
In January 2020, Arena Pharmaceuticals and